Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) Director Jean Jacques Bienaime bought 2,000 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was acquired at an average price of $246.33 per share, for a total transaction of $492,660.00. Following the completion of the purchase, the director directly owned 2,900 shares in the company, valued at approximately $714,357. The trade was a 222.22% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Jean Jacques Bienaime also recently made the following trade(s):
- On Tuesday, May 26th, Jean Jacques Bienaime purchased 400 shares of Ascendis Pharma A/S stock. The stock was acquired at an average cost of $237.80 per share, for a total transaction of $95,120.00.
Ascendis Pharma A/S Stock Performance
Shares of ASND opened at $248.85 on Wednesday. Ascendis Pharma A/S has a 12-month low of $186.05 and a 12-month high of $282.15. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27. The company has a market cap of $15.52 billion, a PE ratio of 19.31 and a beta of 0.39. The stock has a 50-day moving average price of $251.15 and a 200-day moving average price of $237.51.
Analyst Ratings Changes
A number of analysts have recently issued reports on ASND shares. Royal Bank Of Canada lifted their price objective on shares of Ascendis Pharma A/S from $280.00 to $290.00 and gave the stock an “outperform” rating in a report on Friday. BMO Capital Markets started coverage on Ascendis Pharma A/S in a research note on Tuesday. They issued an “outperform” rating and a $319.00 target price on the stock. Jefferies Financial Group restated a “buy” rating and set a $333.00 price target on shares of Ascendis Pharma A/S in a research report on Thursday, August 13th. TD Cowen lifted their price target on Ascendis Pharma A/S from $325.00 to $341.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Barclays cut their price objective on Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating for the company in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of “Buy” and a consensus price target of $300.33.
View Our Latest Stock Report on ASND
Institutional Investors Weigh In On Ascendis Pharma A/S
Institutional investors have recently made changes to their positions in the business. Dearborn Partners LLC purchased a new position in Ascendis Pharma A/S in the 2nd quarter worth $347,000. Public Employees Retirement System of Ohio boosted its position in Ascendis Pharma A/S by 245.4% during the second quarter. Public Employees Retirement System of Ohio now owns 19,977 shares of the biotechnology company’s stock valued at $5,328,000 after buying an additional 14,193 shares during the period. Seven Fleet Capital Management LP grew its stake in shares of Ascendis Pharma A/S by 114.8% during the first quarter. Seven Fleet Capital Management LP now owns 12,179 shares of the biotechnology company’s stock valued at $2,786,000 after buying an additional 6,509 shares during the last quarter. Parallel Advisors LLC grew its stake in shares of Ascendis Pharma A/S by 94.9% during the first quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock valued at $70,000 after buying an additional 148 shares during the last quarter. Finally, Perceptive Advisors LLC increased its holdings in shares of Ascendis Pharma A/S by 41.6% in the first quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock worth $350,282,000 after buying an additional 450,000 shares during the period.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.
The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.
Featured Articles
- Five stocks we like better than Ascendis Pharma A/S
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
